The title of American academician team and the title of an expert of one-thousand people, specializing in oncolytic virus immunity and targeted gene therapy of solid tumors.
Investors 3
| Date | Name | Website |
| - | triwise | en.triwise... |
| - | Octagon Ca... | octagoninv... |
| - | Cowin Capi... | cowincapit... |
Mentions in press and media 5
| Date | Title | Description |
| 08.08.2021 | ImmVira's MVR-C5252 Targeting Brain Tumor Obtained US FDA's Approval for Clinical Trial | |
| 18.07.2021 | ImmVira Launches Pilot-scale Production Line to Expedite the Advancement of Next-generation OV Clinical Trials | |
| 24.09.2020 | ImmVira Group Company Raises US$10M in Strategic Series B Plus Financing | ImmVira Group Company, a Chinese biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, signed US$10m Series B Plus strategic financing. This round of financing will be exclusi... |
| 15.06.2020 | ImmVira Raises $58M in Series B Financing | Immvira Group Company, a Shenzen, China-based biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics, closed a $58m Series B financing. The round was led by Huagai Capital, with... |
| - | Immvira | “Oncolytic Immunotherapy (Oncolytic Immunotherapy)” |